公开(公告)号：US20150368334A1

公开(公告)日：2015-12-24

申请号：US14767117

申请日：2014-02-13

Applicant: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

Inventor： Harry M. Meade ,  Li-How Chen

IPC: C07K16/24

CPC classification number: C07K16/241 ,  A61K39/39508 ,  A61K39/3955 ,  C07K16/04 ,  C07K16/283 ,  C07K2317/12 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

Abstract translation: 一方面，本公开涉及高半乳糖基化抗TNF-α抗体及其组合物。 一方面，本公开涉及具有高水平的半乳糖基化的抗TNF-α抗体群体及其组合物。 一方面，本公开涉及高半乳糖基化抗TNF-α抗体的生产和使用方法以及具有高水平半乳糖基化的抗TNF-α抗体群体。 在一些实施方案中，抗TNF-α抗体是阿达木单抗。

公开(公告)号：US10174110B2

公开(公告)日：2019-01-08

申请号：US14767117

申请日：2014-02-13

Applicant: Laboratoire Français du Fractionnement et des Biotechnologies

Inventor： Harry M. Meade ,  Li-How Chen

IPC: C07K16/24 ,  C07K16/04 ,  A61K39/395 ,  C07K16/28

Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

公开(公告)号：US20190309058A1

公开(公告)日：2019-10-10

申请号：US16192273

申请日：2018-11-15

Applicant: Laboratoire Français du Fractionnement et des Biotechnologies

Inventor： Harry M. Meade ,  Li-How Chen

IPC: C07K16/24 ,  A61K39/395 ,  C07K16/04 ,  C07K16/28

Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

公开(公告)号：US10034921B2

公开(公告)日：2018-07-31

申请号：US14767100

申请日：2014-02-13

Applicant: Laboratoire Français du Fractionnement et des Biotechnologies

Inventor： Li-How Chen ,  Harry M. Meade

IPC: G01N33/00 ,  A01K67/033 ,  A61K38/45 ,  A01K67/027 ,  C12N9/10 ,  C07K14/81

CPC classification number: A61K38/45 ,  A01K67/0275 ,  A01K2207/05 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2267/01 ,  C07K14/8125 ,  C12N9/1081 ,  C12Y204/99

Abstract: In one aspect, the disclosure provides proteins with modified glycosylation and methods of their production. In aspect, the disclosure provides transgenic animals and cells for the production of proteins with modified glycosylation. In some embodiment, the modified glycosylation is increased sialylation.

公开(公告)号：US20180139938A1

公开(公告)日：2018-05-24

申请号：US15571604

申请日：2016-05-04

Applicant: Laboratoire Français du Fractionnement et des, Biotechnologies ,  BioSourcing SA

Inventor： Li-How Chen

IPC: A01K67/027 ,  A61K38/01 ,  C07K14/59 ,  C12N9/10

CPC classification number: A01K67/0275 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2227/102 ,  A01K2227/105 ,  A01K2227/107 ,  A01K2267/01 ,  A61K38/018 ,  A61K2039/505 ,  C07K14/59 ,  C07K2319/01 ,  C07K2319/30 ,  C12N9/1029 ,  C12N9/1081

Abstract: In one aspect, the disclosure provides methods, cells and transgenic non-human mammals for the production of fusion proteins comprising one or more polypeptide fused to an Fc domain, as well as the fusion proteins comprising one or more polypeptide fused to an Fc domain obtained from these methods, cells and transgenic non-human mammals.

公开(公告)号：US20190309057A1

公开(公告)日：2019-10-10

申请号：US16192214

申请日：2018-11-15

Applicant: Laboratoire Français du Fractionnement et des Biotechnologies

Inventor： Harry A. Meade ,  Li-How Chen

IPC: C07K16/24 ,  A61K39/395 ,  C07K16/04 ,  C07K16/28

Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.